Research Reports Coverage on Biotech Stocks -- Radius Health, Vitae Pharma, Global Blood Therapeutics, and Cambrex
NEW YORK, October 26, 2016 /PRNewswire/ --
Companies in the Biotech arena are focused on the research and development of biological substances for the primary purpose of drug discovery and diagnostic development. The industry belongs to the Healthcare sector, which remains volatile due to potential pricing regulations and fiscal policy concerns. On October 13, 2016, research firm Charles Schwab has given the sector a "Market Perform" rating due to the continued need for health care services as well as strong financials. Pre-market, Stock-Callers.com has initiated coverage on the following four equities: Radius Health Inc. (NASDAQ: RDUS), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Global Blood Therapeutics Inc. (NASDAQ: GBT), and Cambrex Corp. (NYSE: CBM). These stocks research reports can be downloaded now by simply registering for free at:
http://stock-callers.com/registration
Radius Health
Waltham, Massachusetts headquartered Radius Health Inc.'s stock finished Tuesday's session 2.94% lower at $46.14. A total volume of 2.37 million shares was traded, which was above their three months average volume of 1.06 million shares. The Company's shares are trading above their 200-day moving average by 12.77%. Furthermore, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have a Relative Strength Index (RSI) of 29.30.
On September 18th, 2016, Radius Health announced that additional positive results from the Phase 3 ACTIVE trial were published in the Journal of Bone and Mineral Research (JBMR). In the article "Effects of Abaloparatide-SC on Fracture and Bone Mineral Density in Subgroups of Postmenopausal Women with Osteoporosis and Varying Baseline Risk Factors" JBMR 2016 Sept 9 [Epub ahead of print] patients in the ACTIVE trial were stratified into pre-specified subgroups of baseline risk factors, inclusive of BMD, prior fracture history and age, to determine the consistency of the response for abaloparatide-SC versus placebo. Your complete research report on RDUS can be retrieved for free at:
http://stock-callers.com/registration/?symbol=RDUS
Vitae Pharma
On Tuesday, shares in Fort Washington, Pennsylvania headquartered Vitae Pharmaceuticals Inc. ended the session flat at $21.00. The stock recorded a three months average volume of 1.05 million shares. The Company's shares have gained 0.29% in the last one month, 88.00% in the previous three months, and 16.02% since the start of this year. The stock is trading 36.59% above its 50-day moving average and 100.40% above its 200-day moving average. Moreover, shares of Vitae Pharmaceuticals, which focuses on discovering and developing novel and small molecule drugs for diseases with unmet medical needs in the US, have an RSI of 90.23.
On October 17th, 2016, Allergan PLC and Vitae Pharmaceuticals announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. Both companies expect the transaction to be completed in Q4 2016. VTAE free report is just a click away at:
http://stock-callers.com/registration/?symbol=VTAE
Global Blood Therapeutics
South California headquartered Global Blood Therapeutics Inc.'s stock ended yesterday's session 11.27% higher at $19.75. A total volume of 2.58 million shares was traded, higher than their three months average volume of 409,740 shares. The Company's shares have advanced 10.58% in the previous three months. The stock is trading 0.15% above its 50-day moving average and 4.79% above its 200-day moving average. Additionally, shares of Global Blood Therapeutics, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 52.86.
On October 24th, 2016, the company that it has reached agreement with the U. S. FDA regarding the design of its pivotal trial for GBT440 in adults and adolescents with sickle cell disease. The Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study is expected to begin screening patients by December with top-line data anticipated in the first half of 2019.
Yesterday, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $66 a share to $73 a share. Sign up for your complimentary research report on GBT at:
http://stock-callers.com/registration/?symbol=GBT
Cambrex
At the close on Tuesday, shares in East Rutherford, New Jersey headquartered Cambrex Corp. recorded a trading volume of 178,790 shares. The stock finished 2.41% lower at $40.55. The Company's shares are trading below their 50-day moving average by 8.63%. Furthermore, shares of Cambrex, which provides various products and services for the development and commercialization of new and generic therapeutics worldwide, have an RSI of 29.82.
On October 07th, 2016, Cambrex announced that it has completed the acquisition of PharmaCore, Inc., a privately-owned company located in High Point, North Carolina, specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects. With the acquisition Cambrex enhances its capabilities and expertise to efficiently develop early clinical phase products and new technologies. Register for free on Stock-Callers.com and download the latest research report on CBM at:
http://stock-callers.com/registration/?symbol=CBM
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article